{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:15:23Z","timestamp":1794539723012,"version":"4.9.1"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41577-026-01316-z","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T10:31:21Z","timestamp":1781865081000},"page":"837-850","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Programming the immunological properties of mRNA vaccines for cancer"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8343-4748","authenticated-orcid":false,"given":"Annette","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5163-3924","authenticated-orcid":false,"given":"Seong Dong","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8138-4250","authenticated-orcid":false,"given":"Benjamin R.","family":"Schrank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-8355","authenticated-orcid":false,"given":"Betty Y. S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4658-055X","authenticated-orcid":false,"given":"Padmanee","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-633X","authenticated-orcid":false,"given":"Wen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"1316_CR1","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41573-024-01042-y","volume":"23","author":"N Pardi","year":"2024","unstructured":"Pardi, N. & Krammer, F. mRNA vaccines for infectious diseases - advances, challenges and opportunities. Nat. Rev. Drug Discov. 23, 838\u2013861 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1316_CR2","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1690918","volume":"247","author":"JA Wolff","year":"1990","unstructured":"Wolff, J. A. et al. Direct gene transfer into mouse muscle in vivo. Science 247, 1465\u20131468 (1990).","journal-title":"Science"},{"key":"1316_CR3","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","volume":"16","author":"JA Kulkarni","year":"2021","unstructured":"Kulkarni, J. A. et al. The current landscape of nucleic acid therapeutics. Nat. Nanotechnol. 16, 630\u2013643 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"1316_CR4","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou, X. et al. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078\u20131094 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"1316_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Karik\u00f3","year":"2005","unstructured":"Karik\u00f3, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165\u2013175 (2005).","journal-title":"Immunity"},{"key":"1316_CR6","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.1016\/j.cell.2025.05.032","volume":"188","author":"M B\u00e9routi","year":"2025","unstructured":"B\u00e9routi, M. et al. Pseudouridine RNA avoids immune detection through impaired endolysosomal processing and TLR engagement. Cell 188, 4880\u20134895.e15 (2025).","journal-title":"Cell"},{"key":"1316_CR7","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41587-022-01525-6","volume":"41","author":"A Dousis","year":"2023","unstructured":"Dousis, A., Ravichandran, K., Hobert, E. M., Moore, M. J. & Rabideau, A. E. An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts. Nat. Biotechnol. 41, 560\u2013568 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1316_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51301-0","volume":"15","author":"J Monroe","year":"2024","unstructured":"Monroe, J. et al. N1-Methylpseudouridine and pseudouridine modifications modulate mRNA decoding during translation. Nat. Commun. 15, 8119 (2024).","journal-title":"Nat. Commun."},{"key":"1316_CR9","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632\u2013644 (2024).","journal-title":"Lancet"},{"key":"1316_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","volume":"585","author":"U Sahin","year":"2020","unstructured":"Sahin, U. et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 585, 107\u2013112 (2020).","journal-title":"Nature"},{"key":"1316_CR11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"1316_CR12","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna, Z. et al. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature 639, 1042\u20131051 (2025).","journal-title":"Nature"},{"key":"1316_CR13","doi-asserted-by":"publisher","first-page":"14604","DOI":"10.1073\/pnas.1209367109","volume":"109","author":"AJ Geall","year":"2012","unstructured":"Geall, A. J. et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl Acad. Sci. USA 109, 14604\u201314609 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1316_CR14","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","volume":"55","author":"R Verbeke","year":"2022","unstructured":"Verbeke, R., Hogan, M. J., Lor\u00e9, K. & Pardi, N. Innate immune mechanisms of mRNA vaccines. Immunity 55, 1993\u20132005 (2022).","journal-title":"Immunity"},{"key":"1316_CR15","doi-asserted-by":"publisher","first-page":"eadf4726","DOI":"10.1126\/sciimmunol.adf4726","volume":"10","author":"V Bhandarkar","year":"2025","unstructured":"Bhandarkar, V., Dinter, T. & Spranger, S. Architects of immunity: how dendritic cells shape CD8+ T cell fate in cancer. Sci. Immunol. 10, eadf4726 (2025).","journal-title":"Sci. Immunol."},{"key":"1316_CR16","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.ccell.2023.06.008","volume":"41","author":"P Meiser","year":"2023","unstructured":"Meiser, P. et al. A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity. Cancer Cell 41, 1498\u20131515 (2023).","journal-title":"Cancer Cell"},{"key":"1316_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane, L. M., Abdel-Hakeem, M. S. & Wherry, E. J. CD8 T cell exhaustion during chronic viral infection and cancer. Annu. Rev. Immunol. 37, 457\u2013495 (2019).","journal-title":"Annu. Rev. Immunol."},{"key":"1316_CR18","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1158\/1078-0432.CCR-20-0305","volume":"26","author":"P Brossart","year":"2020","unstructured":"Brossart, P. The role of antigen spreading in the efficacy of immunotherapies. Clin. Cancer Res. 26, 4442\u20134447 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1316_CR19","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","volume":"50","author":"S Crotty","year":"2019","unstructured":"Crotty, S. T follicular helper cell biology: a decade of discovery and diseases. Immunity 50, 1132\u20131148 (2019).","journal-title":"Immunity"},{"key":"1316_CR20","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/j.chom.2023.10.015","volume":"31","author":"A Ziogas","year":"2023","unstructured":"Ziogas, A., Bruno, M., van der Meel, R., Mulder, W. J. M. & Netea, M. G. Trained immunity: target for prophylaxis and therapy. Cell Host Microbe 31, 1776\u20131791 (2023).","journal-title":"Cell Host Microbe"},{"key":"1316_CR21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","volume":"20","author":"MG Netea","year":"2020","unstructured":"Netea, M. G. et al. Defining trained immunity and its role in health and disease. Nat. Rev. Immunol. 20, 375\u2013388 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1316_CR22","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1038\/s41551-024-01256-w","volume":"8","author":"N Chaudhary","year":"2024","unstructured":"Chaudhary, N. et al. Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d. Nat. Biomed. Eng. 8, 1483\u20131498 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"1316_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102588","volume":"36","author":"O Engstrand","year":"2025","unstructured":"Engstrand, O. et al. Immunogenicity and innate immunity to high-dose and repeated vaccination of modified mRNA versus unmodified mRNA. Mol. Ther. Nucleic Acids 36, 102588 (2025).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1316_CR24","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","volume":"54","author":"M-G Alameh","year":"2021","unstructured":"Alameh, M.-G. et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 54, 2877\u20132892 (2021).","journal-title":"Immunity"},{"key":"1316_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz6893","volume":"6","author":"J Nelson","year":"2020","unstructured":"Nelson, J. et al. Impact of mRNA chemistry and manufacturing process on innate immune activation. Sci. Adv. 6, eaaz6893 (2020).","journal-title":"Sci. Adv."},{"key":"1316_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","volume":"15","author":"M Baiersd\u00f6rfer","year":"2019","unstructured":"Baiersd\u00f6rfer, M. et al. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids 15, 26\u201335 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1316_CR27","doi-asserted-by":"publisher","first-page":"789427","DOI":"10.3389\/fcell.2021.789427","volume":"9","author":"P Morais","year":"2021","unstructured":"Morais, P., Adachi, H. & Yu, Y. T. The critical contribution of pseudouridine to mRNA COVID-19 vaccines. Front. Cell Dev. Biol. 9, 789427 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"1316_CR28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1128\/mr.44.2.175-205.1980","volume":"44","author":"AK Banerjee","year":"1980","unstructured":"Banerjee, A. K. 50\u2019-terminal cap structure in eucaryotic messenger ribonucleic acids. Microbiol. Rev. 44, 175\u2013205 (1980).","journal-title":"Microbiol. Rev."},{"key":"1316_CR29","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/024523a0","volume":"24","author":"T Saito","year":"2008","unstructured":"Saito, T., Owen, D. M., Jiang, F., Marcotrigiano, J. & Gale, M. Jr Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 24, 523\u2013527 (2008).","journal-title":"Nature"},{"key":"1316_CR30","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/mt.2015.103","volume":"23","author":"A Thess","year":"2015","unstructured":"Thess, A. et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol. Ther. 23, 1456\u20131464 (2015).","journal-title":"Mol. Ther."},{"key":"1316_CR31","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","volume":"17","author":"MA Oberli","year":"2017","unstructured":"Oberli, M. A. et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 17, 1326\u20131335 (2017).","journal-title":"Nano Lett."},{"key":"1316_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01124-x","volume":"10","author":"AE Zelkoski","year":"2025","unstructured":"Zelkoski, A. E. et al. Ionizable lipid nanoparticles of mRNA vaccines elicit NF-\u03baB and IRF responses through toll-like receptor 4. npj Vaccines 10, 73 (2025).","journal-title":"npj Vaccines"},{"key":"1316_CR33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk, J. S., Xu, Q., Kim, N., Hanes, J. & Ensign, L. M. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 99, 28\u201351 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1316_CR34","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.chembiol.2019.02.001","volume":"26","author":"A Moreno","year":"2019","unstructured":"Moreno, A. et al. Anti-PEG antibodies inhibit the anticoagulant activity of PEGylated aptamers. Cell Chem. Biol. 26, 634\u2013644.e3 (2019).","journal-title":"Cell Chem. Biol."},{"key":"1316_CR35","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41563-025-02240-8","volume":"24","author":"S Luozhong","year":"2025","unstructured":"Luozhong, S. et al. Poly(carboxybetaine) lipids enhance mRNA therapeutics efficacy and reduce their immunogenicity. Nat. Mater. 24, 1852\u20131861 (2025).","journal-title":"Nat. Mater."},{"key":"1316_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01577-4","author":"Y Zhao","year":"2025","unstructured":"Zhao, Y. et al. Low reactogenicity and high tumour antigen expression from mRNA-LNPs with membrane-destabilizing zwitterionic lipids. Nat. Biomed. Eng. https:\/\/doi.org\/10.1038\/s41551-025-01577-4 (2025).","journal-title":"Nat. Biomed. Eng."},{"key":"1316_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ady6460","volume":"11","author":"Y Zhao","year":"2025","unstructured":"Zhao, Y. et al. Replacing cholesterol and PEGylated lipids with zwitterionic ionizable lipids in LNPs for spleen-specific mRNA translation. Sci. Adv. 11, eady6460 (2025).","journal-title":"Sci. Adv."},{"key":"1316_CR38","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1039\/D0BM01609H","volume":"9","author":"R Zhang","year":"2021","unstructured":"Zhang, R. et al. Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver. Biomater. Sci. 9, 1449\u20131463 (2021).","journal-title":"Biomater. Sci."},{"key":"1316_CR39","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1016\/j.cell.2024.04.003","volume":"187","author":"HR Mendez-Gomez","year":"2024","unstructured":"Mendez-Gomez, H. R. et al. RNA aggregates harness the danger response for potent cancer immunotherapy. Cell 187, 2521\u20132535 (2024).","journal-title":"Cell"},{"key":"1316_CR40","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1038\/s41565-025-02045-5","volume":"20","author":"Dong","year":"2025","unstructured":"Dong et al. A modular mRNA platform for programmable induction of tumour-specific immunogenic cell death. Nat. Nanotechnol. 20, 1856\u20131870 (2025).","journal-title":"Nat. Nanotechnol."},{"key":"1316_CR41","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41565-023-01404-4","volume":"18","author":"X Han","year":"2023","unstructured":"Han, X. et al. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines. Nat. Nanotechnol. 18, 1105\u20131114 (2023).","journal-title":"Nat. Nanotechnol."},{"key":"1316_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abq3500","volume":"8","author":"N Fan","year":"2022","unstructured":"Fan, N. et al. Manganese-coordinated mRNA vaccines with enhanced mRNA expression and immunogenicity induce robust immune responses against SARS-CoV-2 variants. Sci. Adv. 8, eabq3500 (2022).","journal-title":"Sci. Adv."},{"key":"1316_CR43","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adn9961","volume":"10","author":"T Fan","year":"2024","unstructured":"Fan, T. et al. Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity. Sci. Adv. 10, eadn9961 (2024).","journal-title":"Sci. Adv."},{"key":"1316_CR44","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1038\/mt.2016.161","volume":"24","author":"A De Beuckelaer","year":"2016","unstructured":"De Beuckelaer, A. et al. Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses. Mol. Ther. 24, 2012\u20132020 (2016).","journal-title":"Mol. Ther."},{"key":"1316_CR45","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/s41551-025-01380-1","volume":"9","author":"S Qdaisat","year":"2025","unstructured":"Qdaisat, S. et al. Sensitization of tumours to immunotherapy by boosting early type-I interferon responses enables epitope spreading. Nat. Biomed. Eng. 9, 1437\u20131452 (2025).","journal-title":"Nat. Biomed. Eng."},{"key":"1316_CR46","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","volume":"23","author":"S Tahtinen","year":"2022","unstructured":"Tahtinen, S. et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat. Immunol. 23, 532\u2013542 (2022).","journal-title":"Nat. Immunol."},{"key":"1316_CR47","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20241148","volume":"222","author":"BJ Broomfield","year":"2025","unstructured":"Broomfield, B. J. et al. Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection. J. Exp. Med. 222, e20241148 (2025).","journal-title":"J. Exp. Med."},{"key":"1316_CR48","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ads1328","volume":"10","author":"EA Aunins","year":"2025","unstructured":"Aunins, E. A. et al. An Il12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses. Sci. Immunol. 10, eads1328 (2025).","journal-title":"Sci. Immunol."},{"key":"1316_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51411-9","volume":"15","author":"S Kim","year":"2024","unstructured":"Kim, S. et al. Innate immune responses against mRNA vaccine promote cellular immunity through IFN-\u03b2 at the injection site. Nat. Commun. 15, 7226 (2024).","journal-title":"Nat. Commun."},{"key":"1316_CR50","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/s41591-021-01387-6","volume":"27","author":"L Au","year":"2021","unstructured":"Au, L. et al. Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. Nat. Med. 27, 1362\u20131366 (2021).","journal-title":"Nat. Med."},{"key":"1316_CR51","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41577-022-00694-4","volume":"22","author":"J Amersfoot","year":"2022","unstructured":"Amersfoot, J., Eelen, G. & Carmeliet, P. Immunomodulation by endothelial cells \u2014 partnering up with the immune system? Nat. Rev. Immunol. 22, 576\u2013588 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1316_CR52","doi-asserted-by":"publisher","first-page":"E2540","DOI":"10.1073\/pnas.1406674111","volume":"111","author":"SS Tay","year":"2014","unstructured":"Tay, S. S. et al. Antigen expression level threshold tunes the fate of CD8 T cells during primary hepatic immune responses. Proc. Natl Acad. Sci. USA 111, E2540\u2013E2549 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1316_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202211420","volume":"35","author":"K Lam","year":"2023","unstructured":"Lam, K. et al. Optimizing lipid nanoparticles for delivery in primates. Adv. Mater. 35, e2211420 (2023).","journal-title":"Adv. Mater."},{"key":"1316_CR54","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1038\/s41563-025-02284-w","volume":"24","author":"Y Feng","year":"2025","unstructured":"Feng, Y. et al. Albumin-recruiting lipid nanoparticle potentiates the safety and efficacy of mRNA vaccines by avoiding liver accumulation. Nat. Mater. 24, 1826\u20131839 (2025).","journal-title":"Nat. Mater."},{"key":"1316_CR55","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2207841119","volume":"119","author":"J Chen","year":"2022","unstructured":"Chen, J. et al. Lipid nanoparticle-mediated lymph node\u2013targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response. Proc. Natl Acad. Sci. USA 119, e2207841119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1316_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50093-7","volume":"15","author":"K Su","year":"2024","unstructured":"Su, K. et al. Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation. Nat. Commun. 15, 5659 (2024).","journal-title":"Nat. Commun."},{"key":"1316_CR57","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Cheng","year":"2020","unstructured":"Cheng et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotech. 15, 313\u2013320 (2020).","journal-title":"Nat. Nanotech."},{"key":"1316_CR58","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41565-024-01747-6","volume":"20","author":"L Xue","year":"2025","unstructured":"Xue, L. et al. Combinatorial design of siloxane-incorporated lipid nanoparticles augments intracellular processing for tissue-specific mRNA therapeutic delivery. Nat. Nanotech. 20, 132\u2013143 (2025).","journal-title":"Nat. Nanotech."},{"key":"1316_CR59","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3390\/pharmaceutics17040459","volume":"17","author":"J Heredero","year":"2025","unstructured":"Heredero, J. et al. Predictive lung- and spleen-targeted mRNA delivery with biodegradable ionizable lipids in four-component LNPs. Pharmaceutics 17, 459 (2025).","journal-title":"Pharmaceutics"},{"key":"1316_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/ange.202318515","volume":"136","author":"J Lei","year":"2024","unstructured":"Lei, J. et al. Development of mannosylated lipid nanoparticles for mRNA cancer vaccine with high antigen presentation efficiency and immunomodulatory capability. Angew. Chem. 136, e202318515 (2024).","journal-title":"Angew. Chem."},{"key":"1316_CR61","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41551-024-01208-4","volume":"9","author":"D Yin","year":"2025","unstructured":"Yin, D. et al. Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers. Nat. Biomed. Eng. 9, 185\u2013200 (2025).","journal-title":"Nat. Biomed. Eng."},{"key":"1316_CR62","doi-asserted-by":"publisher","first-page":"102107","DOI":"10.1016\/j.mtbio.2025.102107","volume":"34","author":"S Wang","year":"2025","unstructured":"Wang, S. et al. Engineered lipid nanoparticles with synergistic dendritic cell targeting and enhanced endosomal escape for boosted mRNA cancer vaccines. Mater. Today Bio 34, 102107 (2025).","journal-title":"Mater. Today Bio"},{"key":"1316_CR63","doi-asserted-by":"publisher","first-page":"21321","DOI":"10.1021\/jacs.1c09822","volume":"143","author":"S Liu","year":"2021","unstructured":"Liu, S. et al. Zwitterionic phospholipidation of cationic polymers facilitates systemic mRNA delivery to spleen and lymph nodes. J. Am. Chem. Soc. 143, 21321\u201321330 (2021).","journal-title":"J. Am. Chem. Soc."},{"key":"1316_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-67331-1","volume":"17","author":"L Shi","year":"2025","unstructured":"Shi, L. et al. mRNA vaccine developed for sequential selective organ-to-cell targeting of glioma. Nat. Commun. 17, 687 (2025).","journal-title":"Nat. Commun."},{"key":"1316_CR65","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nnano.2008.30","volume":"3","author":"W Jiang","year":"2008","unstructured":"Jiang, W., Kim, B. Y., Rutka, J. T. & Chan, W. C. Nanoparticle-mediated cellular response is size-dependent. Nat. Nanotechnol. 3, 145\u2013150 (2008).","journal-title":"Nat. Nanotechnol."},{"key":"1316_CR66","doi-asserted-by":"publisher","first-page":"101534","DOI":"10.1016\/j.smim.2021.101534","volume":"56","author":"J Kim","year":"2021","unstructured":"Kim, J., Archer, P. A. & Thomas, S. N. Innovations in lymph node targeting nanocarriers. Semin. Immunol. 56, 101534 (2021).","journal-title":"Semin. Immunol."},{"key":"1316_CR67","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7\u201324 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1316_CR68","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817\u2013838 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1316_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33157-4","volume":"13","author":"S Li","year":"2022","unstructured":"Li, S. et al. Payload distribution and capacity of mRNA lipid nanoparticles. Nat. Commun. 13, 5561 (2022).","journal-title":"Nat. Commun."},{"key":"1316_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53914-x","volume":"15","author":"S Liu","year":"2024","unstructured":"Liu, S. et al. Charge-assisted stabilization of lipid nanoparticles enables inhaled mRNA delivery for mucosal vaccination. Nat. Commun. 15, 9471 (2024).","journal-title":"Nat. Commun."},{"key":"1316_CR71","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","volume":"621","author":"H Zhang","year":"2023","unstructured":"Zhang, H. et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature 621, 396\u2013403 (2023).","journal-title":"Nature"},{"key":"1316_CR72","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jamaoncol.2024.5927","volume":"11","author":"K Ramalingam","year":"2025","unstructured":"Ramalingam, K. et al. Intratumoral injection of mRNA-2752 and pembrolizumab for high-risk ductal carcinoma in situ: a phase 1 nonrandomized clinical trial. JAMA Oncol. 11, 288\u2013292 (2025).","journal-title":"JAMA Oncol."},{"key":"1316_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54877-9","volume":"15","author":"AE Hamouda","year":"2024","unstructured":"Hamouda, A. E. et al. Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity. Nat. Commun. 15, 10635 (2024).","journal-title":"Nat. Commun."},{"key":"1316_CR74","doi-asserted-by":"publisher","first-page":"CT032","DOI":"10.1158\/1538-7445.AM2020-CT032","volume":"80","author":"A Jimeno","year":"2020","unstructured":"Jimeno, A. et al. Abstract CT032: a phase 1\/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies. Cancer Res. 80, CT032\u2013CT032 (2020).","journal-title":"Cancer Res."},{"key":"1316_CR75","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg7836","volume":"6","author":"KA Connolly","year":"2021","unstructured":"Connolly, K. A. et al. A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response. Sci. Immunol. 6, eabg7836 (2021).","journal-title":"Sci. Immunol."},{"key":"1316_CR76","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nm.3105","volume":"19","author":"Y Hailemichael","year":"2013","unstructured":"Hailemichael, Y. et al. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion. Nat. Med. 19, 465\u2013472 (2013).","journal-title":"Nat. Med."},{"key":"1316_CR77","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201966","volume":"219","author":"M Shakiba","year":"2022","unstructured":"Shakiba, M. et al. TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. J. Exp. Med. 219, e20201966 (2022).","journal-title":"J. Exp. Med."},{"key":"1316_CR78","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41590-024-02044-z","volume":"26","author":"S Singhaviranon","year":"2025","unstructured":"Singhaviranon, S. et al. Low-avidity T cells drive endogenous tumor immunity in mice and humans. Nat. Immunol. 26, 240\u2013251 (2025).","journal-title":"Nat. Immunol."},{"key":"1316_CR79","doi-asserted-by":"publisher","unstructured":"McCarron, M. et al. Cross-competition shapes CD8+ T cell hierarchies and differentiation after RNA vaccination. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.10.26.684631 (2025).","DOI":"10.1101\/2025.10.26.684631"},{"key":"1316_CR80","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/vaccines12030318","volume":"12","author":"Silva-Pilipich","year":"2024","unstructured":"Silva-Pilipich et al. Self-amplifying RNA: a second revolution of mRNA vaccines against COVID-19. Vaccines 12, 318 (2024).","journal-title":"Vaccines"},{"key":"1316_CR81","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","volume":"27","author":"Z Hu","year":"2021","unstructured":"Hu, Z. et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat. Med. 27, 515\u2013525 (2021).","journal-title":"Nat. Med."},{"key":"1316_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47425-y","volume":"15","author":"M Lauss","year":"2024","unstructured":"Lauss, M. et al. Molecular patterns of resistance to immune checkpoint blockade in melanoma. Nat. Commun. 15, 3075 (2024).","journal-title":"Nat. Commun."},{"key":"1316_CR83","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.ccell.2024.05.025","volume":"42","author":"G Espinosa-Carrasco","year":"2024","unstructured":"Espinosa-Carrasco, G. et al. Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell 42, 1202\u20131216.e8 (2024).","journal-title":"Cancer Cell"},{"key":"1316_CR84","doi-asserted-by":"publisher","first-page":"7461","DOI":"10.1016\/j.cell.2025.11.023","volume":"188","author":"D Casta\u00f1o","year":"2025","unstructured":"Casta\u00f1o, D. et al. Distinct components of mRNA vaccines cooperate to instruct efficient germinal center responses. Cell 188, 7461\u20137480.e23 (2025).","journal-title":"Cell"},{"key":"1316_CR85","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1200\/JCO.2007.15.0284","volume":"26","author":"MC Dieu-Nosjean","year":"2008","unstructured":"Dieu-Nosjean, M. C. et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 26, 4410\u20134417 (2008).","journal-title":"J. Clin. Oncol."},{"key":"1316_CR86","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1084\/jem.20171450","volume":"215","author":"N Pardi","year":"2018","unstructured":"Pardi, N. et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J. Exp. Med. 215, 1571\u20131588 (2018).","journal-title":"J. Exp. Med."},{"key":"1316_CR87","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1158\/0008-5472.CAN-18-2867","volume":"79","author":"OAW Haabeth","year":"2019","unstructured":"Haabeth, O. A. W. et al. Local delivery of Ox40l, Cd80, and Cd86 mRNA kindles global anticancer immunity. Cancer Res. 79, 1624\u20131634 (2019).","journal-title":"Cancer Res."},{"key":"1316_CR88","doi-asserted-by":"publisher","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","volume":"16","author":"Y Ju","year":"2022","unstructured":"Ju, Y. et al. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. ACS Nano 16, 11769\u201311780 (2022).","journal-title":"ACS Nano"},{"key":"1316_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24285-4","volume":"12","author":"P Jalkanen","year":"2021","unstructured":"Jalkanen, P. et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat. Commun. 12, 3991 (2021).","journal-title":"Nat. Commun."},{"key":"1316_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66993-1","volume":"17","author":"X Cui","year":"2025","unstructured":"Cui, X. et al. Impact of pre-existing anti-replicase immunity on the efficacy of self-amplifying mRNA vaccines. Nat. Commun. 17, 278 (2025).","journal-title":"Nat. Commun."},{"key":"1316_CR91","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imr.12939","volume":"299","author":"D Michaud","year":"2021","unstructured":"Michaud, D., Steward, C. R., Mirlekar, B. & Pylayeva-Gupta, Y. Regulatory B cells in cancer. Immunol. Rev. 299, 74\u201392 (2021).","journal-title":"Immunol. Rev."},{"key":"1316_CR92","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1098","volume":"352","author":"MG Netea","year":"2016","unstructured":"Netea, M. G. et al. Trained immunity: a program of innate immune memory in health and disease. Science 352, aaf1098 (2016).","journal-title":"Science"},{"key":"1316_CR93","doi-asserted-by":"publisher","first-page":"17537","DOI":"10.1073\/pnas.1202870109","volume":"109","author":"J Kleinnijenhuis","year":"2012","unstructured":"Kleinnijenhuis, J. et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc. Natl Acad. Sci. USA 109, 17537\u201317542 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1316_CR94","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.chom.2017.12.010","volume":"23","author":"RJ Arts","year":"2018","unstructured":"Arts, R. J. et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe 23, 89\u2013100.e105 (2018).","journal-title":"Cell Host Microbe"},{"key":"1316_CR95","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.cell.2016.09.034","volume":"167","author":"B Novakovic","year":"2016","unstructured":"Novakovic, B. et al. \u03b2-glucan reverses the epigenetic state of LPS-induced immunological tolerance. Cell 167, 1354\u20131368.e14 (2016).","journal-title":"Cell"},{"key":"1316_CR96","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.immuni.2020.10.011","volume":"54","author":"S Fanucchi","year":"2021","unstructured":"Fanucchi, S., Dom\u00ednguez-Andr\u00e9s, J., Joosten, L. A. B., Netea, M. G. & Mhlanga, M. M. The intersection of epigenetics and metabolism in trained immunity. Immunity 54, 32\u201343 (2021).","journal-title":"Immunity"},{"key":"1316_CR97","doi-asserted-by":"publisher","DOI":"10.1126\/science.1250684","volume":"345","author":"SC Cheng","year":"2014","unstructured":"Cheng, S. C. et al. mTOR- and HIF-1\u03b1-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 345, 1250684 (2014).","journal-title":"Science"},{"key":"1316_CR98","doi-asserted-by":"publisher","first-page":"1251086","DOI":"10.1126\/science.1251086","volume":"345","author":"S Saeed","year":"2014","unstructured":"Saeed, S. et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science 345, 1251086 (2014).","journal-title":"Science"},{"key":"1316_CR99","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s44320-025-00093-6","volume":"21","author":"A Simonis","year":"2025","unstructured":"Simonis, A. et al. Persistent epigenetic memory of SARS-CoV-2 mRNA vaccination in monocyte-derived macrophages. Mol. Syst. Biol. 21, 341\u2013360 (2025).","journal-title":"Mol. Syst. Biol."},{"key":"1316_CR100","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.cell.2017.11.025","volume":"172","author":"S Bekkering","year":"2018","unstructured":"Bekkering, S. et al. Metabolic induction of trained immunity through the mevalonate pathway. Cell 172, 135\u2013146.e9 (2018).","journal-title":"Cell"},{"key":"1316_CR101","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.cell.2020.09.059","volume":"183","author":"B Priem","year":"2020","unstructured":"Priem, B. et al. Trained immunity-promoting nanobiologic therapy suppresses tumor growth and potentiates checkpoint inhibition. Cell 183, 786\u2013801.e719 (2020).","journal-title":"Cell"},{"key":"1316_CR102","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41590-022-01388-8","volume":"24","author":"C Ding","year":"2023","unstructured":"Ding, C. et al. Inducing trained immunity in pro-metastatic macrophages to control tumor metastasis. Nat. Immunol. 24, 239\u2013254 (2023).","journal-title":"Nat. Immunol."},{"key":"1316_CR103","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.163347","volume":"7","author":"Y Yamaguchi","year":"2022","unstructured":"Yamaguchi, Y. et al. Consecutive BNT162b2 mRNA vaccination induces short-term epigenetic memory in innate immune cells. JCI Insight 7, e163347 (2022).","journal-title":"JCI Insight"},{"key":"1316_CR104","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41565-024-01847-3","volume":"20","author":"SRJ Hofstraat","year":"2025","unstructured":"Hofstraat, S. R. J. et al. Nature-inspired platform nanotechnology for RNA delivery to myeloid cells and their bone marrow progenitors. Nat. Nanotechnol. 20, 532\u2013542 (2025).","journal-title":"Nat. Nanotechnol."},{"key":"1316_CR105","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202504830","volume":"38","author":"MM Trines","year":"2026","unstructured":"Trines, M. M. et al. Dendrimers improve apolipoprotein nanoparticle mRNA delivery to immune cells. Adv. Mater. 38, e04830 (2026).","journal-title":"Adv. Mater."},{"key":"1316_CR106","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s10875-025-01977-w","volume":"46","author":"M Kunc","year":"2025","unstructured":"Kunc, M. et al. Signatures of trained immunity following mRNA vaccination: differences between mRNA-1273 and BNT162b2. J. Clin. Immunol. 46, 8 (2025).","journal-title":"J. Clin. Immunol."},{"key":"1316_CR107","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/s41423-022-00903-z","volume":"19","author":"J Chen","year":"2022","unstructured":"Chen, J. et al. Tumor-associated macrophage (TAM)-derived CCL22 induces FAK addiction in esophageal squamous cell carcinoma (ESCC). Cell. Mol. Immunol. 19, 1054\u20131066 (2022).","journal-title":"Cell. Mol. Immunol."},{"key":"1316_CR108","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev, A. et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39, 845\u2013865. e847 (2021).","journal-title":"Cancer Cell"},{"key":"1316_CR109","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.immuni.2022.10.002","volume":"55","author":"BG Nixon","year":"2022","unstructured":"Nixon, B. G. et al. Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer. Immunity 55, 2044\u20132058.e2045 (2022).","journal-title":"Immunity"},{"key":"1316_CR110","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005356","volume":"12","author":"CR Cunningham","year":"2016","unstructured":"Cunningham, C. R. et al. Type I and type II interferon coordinately regulate suppressive dendritic cell fate and function during viral persistence. PLoS Pathog. 12, e1005356 (2016).","journal-title":"PLoS Pathog."},{"key":"1316_CR111","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.3389\/fimmu.2018.02129","volume":"9","author":"AV Bazhin","year":"2018","unstructured":"Bazhin, A. V., von Ahn, K., Fritz, J., Werner, J. & Karakhanova, S. Interferon-\u03b1 up-regulates the expression of PD-L1 molecules on immune cells through STAT3 and p38 signaling. Front. Immunol. 9, 2129 (2018).","journal-title":"Front. Immunol."},{"key":"1316_CR112","first-page":"90","volume":"116","author":"K Evel-Kabler","year":"2006","unstructured":"Evel-Kabler, K., Song, X. T., Aldrich, M., Huang, X. F. & Chen, S. Y. SOCS1 restricts dendritic cells\u2019 ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J. Clin. Immunol. 116, 90\u2013100 (2006).","journal-title":"J. Clin. Immunol."},{"key":"1316_CR113","doi-asserted-by":"publisher","first-page":"CT183","DOI":"10.1158\/1538-7445.AM2022-CT183","volume":"82","author":"BA Carneiro","year":"2022","unstructured":"Carneiro, B. A. et al. Abstract CT183: first-in-human study of MEDI1191 (mRNA encoding IL-12) plus durvalumab in patients (pts) with advanced solid tumors. Cancer Res. 82, CT183\u2013CT183 (2022).","journal-title":"Cancer Res."},{"key":"1316_CR114","doi-asserted-by":"publisher","first-page":"102575","DOI":"10.1016\/j.xcrm.2025.102575","volume":"7","author":"S Onkar","year":"2026","unstructured":"Onkar, S., Bozkus, C. C., Saxena, M. & Bhardwaj, N. Pipe dream to pipeline: journey of cancer vaccines and the road ahead. Cell Rep. Med. 7, 102575 (2026).","journal-title":"Cell Rep. Med."},{"key":"1316_CR115","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41590-020-00810-3","volume":"22","author":"Baharom","year":"2021","unstructured":"Baharom et al. Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+T cells. Nat. Immunol. 22, 41\u201352 (2021).","journal-title":"Nat. Immunol."},{"key":"1316_CR116","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.1016\/j.cell.2021.08.020","volume":"184","author":"ML Burger","year":"2021","unstructured":"Burger, M. L. et al. Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors. Cell 184, 4996\u20135014.e26 (2021).","journal-title":"Cell"},{"key":"1316_CR117","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1158\/0008-5472.CAN-21-1230","volume":"82","author":"M Janghorban","year":"2022","unstructured":"Janghorban, M. et al. Single-cell analysis unveils the role of the tumor immune microenvironment and notch signaling in dormant minimal residual disease. Cancer Res. 82, 885\u2013899 (2022).","journal-title":"Cancer Res."},{"key":"1316_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115745","volume":"44","author":"K Zhang","year":"2025","unstructured":"Zhang, K. et al. Heterologous prime-boost with an mRNA vaccine and an oncolytic virus enhances tumor regression through overcoming intratumoral immune suppression. Cell Rep. 44, 115745 (2025).","journal-title":"Cell Rep."},{"key":"1316_CR119","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.vaccine.2015.11.062","volume":"34","author":"K Kardani","year":"2016","unstructured":"Kardani, K., Bolhassani, A. & Shahbazi, S. Prime-boost vaccine strategy against viral infections: mechanisms and benefits. Vaccine 34, 413\u2013423 (2016).","journal-title":"Vaccine"},{"key":"1316_CR120","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","volume":"398","author":"X Liu","year":"2021","unstructured":"Liu, X. et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet 398, 856\u2013869 (2021).","journal-title":"Lancet"},{"key":"1316_CR121","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","volume":"28","author":"CD Palmer","year":"2022","unstructured":"Palmer, C. D. et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 28, 1619\u20131629 (2022).","journal-title":"Nat. Med."},{"key":"1316_CR122","doi-asserted-by":"publisher","first-page":"5125","DOI":"10.1016\/j.cell.2025.06.019","volume":"188","author":"E Blass","year":"2025","unstructured":"Blass, E. et al. A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma. Cell 188, 5125\u20135141.e27 (2025).","journal-title":"Cell"},{"key":"1316_CR123","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41586-025-09655-y","volume":"647","author":"AJ Grippin","year":"2025","unstructured":"Grippin, A. J. et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature 647, 488\u2013497 (2025).","journal-title":"Nature"},{"key":"1316_CR124","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00262-018-2117-0","volume":"67","author":"L Basler","year":"2018","unstructured":"Basler, L. et al. Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model. Cancer Immunol. Immunother. 67, 653\u2013662 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"1316_CR125","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen, A. et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat. Med. 29, 2844\u20132853 (2023).","journal-title":"Nat. Med."},{"key":"1316_CR126","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","volume":"31","author":"J Lopez","year":"2025","unstructured":"Lopez, J. et al. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nat. Med. 31, 152\u2013164 (2025).","journal-title":"Nat. Med."}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01316-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01316-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01316-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:01:39Z","timestamp":1793106099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01316-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":126,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1316"],"URL":"https:\/\/doi.org\/10.1038\/s41577-026-01316-z","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"18 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.S. reports consulting fees from Achelois, Affini-T, Akoya Biosciences, Apricity, AsherBio, BioAtla, Candel Therapeutics, Catalio, C-Reveal Therapeutics, Dragonfly, Earli, Enable Medicine, Glympse, Henlius\/Hengenix, Hummingbird, ImaginAb, Intervenn Biosciences, LAVA Therapeutics, Lytix, Marker, Matrisome, NTx, Oncolytics, Osteologic, PBM Capital, Phenomic AI, Polaris Pharma, Trained Therapeutix, Two Bear Capital, Vironexis and Xilis; and ownership of stocks in Adaptive Bio, BioNTech, JSL Health, Sporos and Time Bioventures. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}